The top 20 biopharmaceutical companies experienced mixed performance in 2024 amid a dynamic landscape influenced by various ...

We recently published a list of 10 AI News and Ratings You Should Not Miss. In this article, we are going to take a look at ...

Cognizant and Gilead expand partnership to drive greater value through advanced technology applications: Teaneck, New Jersey Friday, January 31, 2025, 14:00 Hrs [IST] Cognizant ha ...

Bernstein analyst Courtney Breen maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of ...

Gilead is expected to enhance its efficiency through leveraging Cognizant’s expertise in AI and advanced technology ...

Cognizant (CTSH) has announced an expansion of its longstanding relationship with biopharmaceutical leader Gilead Sciences (GILD) that aims to ...

Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth.

Gilead Sciences, Inc. (NASDAQ:GILD), a leading biopharmaceutical company with a market capitalization of $119.32 billion, has been making significant strides in its core HIV franchise while expanding ...

Gilead Sciences Inc. must face a fired employee’s lawsuit alleging its response to a co-worker’s false sexual harassment ...

In the assessment of 12-month price targets, analysts unveil insights for Gilead Sciences, presenting an average target of ...

Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...

The stock's fall snapped a two-day winning streak.